Author: GlobeNewswire

PARIS and CAMBRIDGE, Mass., Jan. 29, 2025 (GLOBE NEWSWIRE) — NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a…

DURHAM, N.C., Jan. 29, 2025 (GLOBE NEWSWIRE) — Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop…

TORONTO, Jan. 29, 2025 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a…

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 29, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical…

SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) — Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is…

REDWOOD CITY, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing…

BASEL, Switzerland and LONDON and NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) — Roivant (Nasdaq: ROIV) today announced that it…

IRVINE, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros,…

REDWOOD CITY, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel…

As previously reported1, the study met the primary efficacy endpoint for the treatment with lanifibranor 800mg demonstrating a 44% reduction…